Numerous targeted and large-scale studies have demonstrated that IDH mutation and 1p/19q-cd are the well-recognized prognostic factors in glioma that often lead to high sensitivity to chemotherapy (Cairncross et al., 2013). The gene discussed is IDH2; the disease is central nervous system cancer.